Nuvation Bio (NUVB) Q1 2026 earnings summary

Executive summary

• Achieved strong commercial momentum for Ibtrozi in ROS1-positive NSCLC, with over 600 new patient starts since launch and a shift toward first-line use exceeding 50% of new starts, driving revenue stacking and longer therapy duration.

• Ibtrozi added to NCCN CNS guidelines, reinforcing its differentiated clinical profile and CNS activity for patients with brain metastases.

• Safusidenib program advanced, with exclusive rights acquired for Japan and pivotal SIGMA Phase III trial expansion; 12 of 27 patients remain on treatment in Phase 2 with over 5 years median follow-up.

• Entered an exclusive license and collaboration agreement with Eisai for taletrectinib in Europe, Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, and parts of Asia, expanding global reach outside the U.S., China, and Japan.

• Eisai receives exclusive development, registration, and commercialization rights for taletrectinib in the licensed territories; Nuvation Bio retains U.S. rights and leads global development.

Financial highlights

• Q1 2026 total revenue was $83.2 million, including $18.5 million in Ibtrozi net U.S. product revenue, up 18% sequentially.

• Collaboration and license revenue reached $64.7 million, including a $58.7 million upfront payment from Eisai.

• Net income for Q1 2026 was $5.4 million, compared to a net loss of $53.2 million in Q1 2025.

• Operating expenses totaled $73.5 million, with R&D at $35 million and SG&A at $38.3 million.

• Ended the quarter with $533.7 million in cash, equivalents, and marketable securities.

Outlook and guidance

• Expect continued growth in first-line patient starts and revenue stacking as late-line pool depletes.

• Gross-to-net expected to stabilize around 30% as price increases and 340B/Medicaid dynamics normalize.

• Anticipate $30 million milestone payment upon Ibtrozi approval in Europe in H1 2027.

• Eisai will prioritize taletrectinib as its flagship oncology product in NSCLC in the EU and beyond, aiming to establish it as a standard of care.

• Plans to present longer-term safusidenib Phase 2 data and advance the pivotal Phase 3 SIGMA study.